Once-Weekly Insulin Is Here. It’s Still Not Reversal.

The FDA just approved the first once-weekly basal insulin for Type 2 diabetes — Novo Nordisk’s Awiqli, greenlit on March 26, 2026 per the FDA Novel Drug Approvals 2026 list, with the U.S. launch expected in the second half of this year. The pitch is simple: one shot a week instead of seven. For the 38 million Americans living with Type 2 diabetes, that’s being marketed as a quality-of-life breakthrough. It is — for managing the disease. It is not, and cannot be, a reversal.

What Just Happened

Awiqli is the first and only once-weekly basal insulin approved in the United States, indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. The FDA approval was based on the ONWARDS Phase 3a program — five randomized, active-controlled trials detailed in the Awiqli Prescribin Information, enrolling roughly 1,880 adults with Type 2 diabetes, comparing once-weekly insulin icodec to once-daily basal insulins like insulin glargine U-100 and insulin degludec U-100.

The headline numbers from the FDA label and clinical review (covered in detail by AJMC’s report on the approval):

  • HbA1c reduction in insulin-naïve patients: Awiqli cut A1c by 0.18% more than insulin glargine U-100 at 52 weeks, and 0.22% more than insulin degludec U-100 at 26 weeks — statistically significant superiority per the Awiqli Prescribing Information.
  • In basal-bolus patients: Awiqli achieved similar glycemic control to once-daily comparators, per the FDA approval review
  • Injection burden: Seven injections per week collapsed to one, as Novo Nordisk announced in their March 26, 2026 press release
  • Safety profile: Consistent with the basal insulin class — hypoglycemia and injection-site reactions are the notable risks, according to the FDA approval review and AJMC’s coverage.

The Question Nobody’s Asking

Here’s what every headline about Awiqli is leaving out: this drug still manages diabetes. It does not reverse it.

Insulin icodec works the same way every basal insulin has worked since 1922 — by replacing the hormone your pancreas isn’t making enough of. You inject it. It lowers your blood sugar. When you stop, the A1c climbs back. The underlying insulin resistance never gets addressed. The beta-cell dysfunction never gets addressed. The medication overrides the symptom while the disease keeps running the show.

That’s not a flaw. That’s pharmacology. Every insulin — daily, weekly, or inhaled — is a lifelong lease on disease management, not a deed to remission. Going from seven shots a week to one is a real quality-of-life win for patients who need insulin. But “more convenient insulin” and “reversal of Type 2 diabetes” are two completely different games.

So the real question for the millions of Americans being told they’ll be on insulin for life isn’t “which insulin
should I take?” It’s “why am I still diabetic in the first place, and what’s actually required to reverse it?”

So the real question for the millions of Americans being told they’ll be on insulin for life isn’t “which insulin should I take?” It’s “why am I still diabetic in the first place, and what’s actually required to reverse it?”

What Reversal Actually Looks Like

At Diabetes Reversal Group, we measure reversal by a single, unblinking standard: A1c below 6.4% — off
every diabetes medication — sustained. Not “controlled.” Not “managed.” Reversed.

Our patients hit an average completion A1c of 5.7% — well below the diabetic threshold — in an average of
4.5 months. The mechanism isn’t a molecule. It’s a system: a patented nutrition protocol (240 recipes, 7-day meal plans, telemedicine delivery, mobile app coaching) that reverses the underlying insulin resistance at the root. The world’s only patented protocol for Type 2 diabetes reversal (U.S. patent granted September 2020), built on 16 years of clinical use with 10,000+ patients.

You can read patient outcomes — A1cs before and after, medications discontinued, time to reversal — at
diabetesreversalgroup.com/testimonial/

The Bottom Line

A once-weekly insulin is a real win for patients who need insulin. A system that reverses the disease is a different game entirely — one the pharmaceutical pipeline cannot build.

If you’re on metformin, a GLP-1, or insulin, and you’ve been told you’ll be on it for life, you owe it to yourself to
look at what’s actually possible. Watch our free webinar — the same presentation our medical team uses with new patients — No pitch. Just the science, the data, and how to know if you’re a candidate.

By: Dr. Jeffrey Hockings / Co-Founder/CEO / Diabetes Reversal Group / Kristine Burke, MD / Chief Medical
Officer / Diabetes Reversal Group.

The only patented system in the world proven to reverse Type 2 diabetes.